Stemline Therapeutics (STML) vs. Trevena (TRVN) Head to Head Survey
Trevena (NASDAQ: TRVN) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitabiliy, dividends and earnings.
Volatility & Risk
Trevena has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Comparatively, Stemline Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Trevena and Stemline Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trevena presently has a consensus target price of $11.73, indicating a potential upside of 409.88%. Stemline Therapeutics has a consensus target price of $32.60, indicating a potential upside of 252.43%. Given Trevena’s higher possible upside, analysts clearly believe Trevena is more favorable than Stemline Therapeutics.
Earnings and Valuation
This table compares Trevena and Stemline Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Trevena||$1.88 million||71.33||-$105.20 million||($1.97)||-1.17|
|Stemline Therapeutics||$1.14 million||189.67||-$44.34 million||($2.31)||-4.00|
Stemline Therapeutics has higher revenue, but lower earnings than Trevena. Stemline Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
64.5% of Trevena shares are owned by institutional investors. Comparatively, 54.2% of Stemline Therapeutics shares are owned by institutional investors. 4.6% of Trevena shares are owned by company insiders. Comparatively, 15.7% of Stemline Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Trevena and Stemline Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.